Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Harrison

Cardiovascular Disease Santa Maria, CA Medical Doctor

NPI 1396934188 CMS profile 289897

1510 E Main St, Suite 101, Santa Maria, CA 93454

Open in the dashboard

General payments

$13,604

473 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$21,563 paid to institutions, not to them · program year 2025

Through program year 2025, Alexander Harrison of Santa Maria, CA is reported in the CMS Open Payments database as having received $13,604 across 473 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $21,563 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,812 86
2024 General $2,945 89
2023 General $2,048 71
2022 General $1,370 66
2021 General $982 40
2020 General $747 39
2019 General $3,701 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Harrison
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Alexander Harrison were reported at $1,812. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Alexander Harrison Cardiovascular Disease median Middle half National median
2019 $3,701 $450 $127–$1,392 $163
2020 $747 $242 $77–$751 $114
2021 $982 $335 $101–$1,037 $132
2022 $1,370 $395 $121–$1,211 $149
2023 $2,048 $443 $136–$1,283 $160
2024 $2,945 $450 $136–$1,323 $164
2025 $1,812 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $4,536 34 payments
  2. Amgen Inc. $1,458 110 payments
  3. Boston Scientific Corporation $1,309 32 payments
  4. Novartis Pharmaceuticals Corporation $775 45 payments
  5. Merck Sharp & Dohme Corporation $673 26 payments
  6. AstraZeneca Pharmaceuticals LP $614 28 payments
  7. Esperion Therapeutics, Inc. $481 21 payments
  8. E.R. Squibb & Sons, L.L.C. $456 25 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $393 18 payments
  10. Medtronic, Inc. $322 8 payments
  11. Other $2,588 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,425 457 payments
  2. Travel and Lodging $3,032 11 payments
  3. Education $147 5 payments
Products named General payments · program years 2019–2025
  1. Allure CRT Pacemaker $1,915 10 payments
  2. Repatha Cardiology $1,105 92 payments
  3. AVEIR $957 5 payments
  4. VERQUVO $704 31 payments
  5. NEXLETOL $481 21 payments
  6. LEQVIO $395 20 payments
  7. WATCHMAN Access System $388 7 payments
  8. REPATHA Cardiovascular $353 18 payments
  9. ELIQUIS $344 19 payments
  10. Corlanor $324 22 payments
  11. Other $7,248 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

4,014

Median for Cardiology: 2,533

Drug cost

$895,580

Median for Cardiology: $485,213

Branded share of claims

26%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 367 $436,390
Repatha Sureclick Evolocumab Brand 119 $109,402
Xarelto Rivaroxaban Brand 85 $100,903
Entresto Sacubitril/Valsartan Brand 72 $94,711
Farxiga Dapagliflozin Propanediol Brand 37 $35,095
Jardiance Empagliflozin Brand 19 $25,709
Praluent Pen Alirocumab Brand 14 $14,869
Ezetimibe Generic 328 $9,872
Vascepa Icosapent Ethyl Brand 11 $9,795
Multaq Dronedarone Hcl Brand 11 $8,418

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$917,264

Of which drugs: $4,952

Medicare patients

2,197

Average age 76

Services billed

11,814

1,102 women, 1,095 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 47%
Arthritis 46%
Diabetes 39%
Atrial fibrillation 39%
Chronic kidney disease 35%
Heart failure 30%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 204 817 $4,270
Injection, aminophyllin, up to 250 mg J0280 Office 96 96 $682

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $218
$218 119 —
VERQUVO
  • Merck Sharp & Dohme Corporation $174
$174 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $167
$167 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $121
$121 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $102
$102 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record